Combination therapy with ARN3261 and olaparib synergistically decreased cell viability at the doses optimized for synergy using 2 PARP inhibitor–resistant ovarian cancer cell lines (unpublished observations). The gene discussed is PARP1; the disease is ovarian carcinoma.